Clinical behaviour and outcome in pediatric glioblastoma: current scenario

Radiat Oncol J. 2021 Mar;39(1):72-77. doi: 10.3857/roj.2020.00591. Epub 2021 Mar 30.


Pediatric glioblastoma (pGBM) is a rare entity accounting for only approximately 3% of all childhood brain tumors. Treatment guidelines for pGBM have been extrapolated from those in adult glioblastoma. Rarity of pGBM and underrepresentation of pediatric population in major studies precludes from defining the ideal treatment protocol for these patients. Maximum safe resection is performed in most of the cases followed by postoperative radiotherapy in children over 3 years of age. Benefit of temozolomide is unclear in these patients. Here, we present the clinicopathological details and outcome of six pGBM patients treated at our institute in 2018-2019.

Keywords: Child; Genetics; Glioblastoma; Radiotherapy; Temozolomide.

Publication types

  • Case Reports